Effect of ambroxol on pneumonia caused by pseudomonas aeruginosa with biofilm formation in an endotracheal intubation rat model

Chemotherapy

Volumn 57, Issue 2, 2011, Pages 173-180

  Li, Fang ^a   Wang, Wenlei ^a   Hu, Linyan ^a   Li, Luquan ^a   Yu, Jialin ^a,b  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b NONE   (China)

Author keywords

Ambroxol; Biofilm; Endotracheal intubation; Pneumonia; Pseudomonas aeruginosa

Indexed keywords

AMBROXOL; GAMMA INTERFERON; INTERLEUKIN 10; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATELECTASIS; BACTERIAL COUNT; BACTERIAL LOAD; BACTERIAL STRAIN; BIOFILM; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DRUG EFFECT; ENDOTRACHEAL INTUBATION; FEMALE; HISTOPATHOLOGY; LUNG ABSCESS; LUNG EMPHYSEMA; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; RAT; SCANNING ELECTRON MICROSCOPY; VENTILATOR ASSOCIATED PNEUMONIA;

AMBROXOL; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BACTERIAL LOAD; BIOFILMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; INTERFERON-GAMMA; INTERLEUKIN-10; INTUBATION, INTRATRACHEAL; LUNG; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79953204002     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323622     Document Type: Article

References (26)

1. Gaynes RP, Edwards JR, Jarvis WR, Culver DH, Tolson JS, Martone WJ, the National Nosocomial Infection Surveillance System: Nosocomial infections among neonates in high-risk nurseries in the United States. Pediatrics 1996; 5: 357-361. (Pubitemid 26295834)
2. Coutinho HDM, Costa JGM, Lima EO, et al: Enhancement of the antibiotic activity against a multiresistant Escherichia coli by Mentha arvensis L. and chlorpromazine. Chemotherapy 2008; 54: 328-330.
3. Foglia E, Hollenbeak C, Fraser V, Elward A: Costs associated with nosocomial bloodstream infections and ventilator-associated pneumonia in pediatric intensive care unit patients (abstract). 16th Annu Meet Soc Healthcare Epidemiol Am 2006; 109-112.
4. Babcock HM, Zack JE, Garrison T, Trovollion E, Kollef MH, Fraser VJ: Ventilator-associated pneumonia in a multi-hospital system: differences in microbiology by location. Infect Control Hosp Epidemiol 2003; 4: 853-858. (Pubitemid 37516817)
5. Güzel CB, Gerçeker AA: In vitro activities of various antibiotics, alone and in combination with colistin methanesulfonate, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Chemotherapy 2008; 54: 147-151. (Pubitemid 351448602)
6. Murphy TF, Brauer AL, Eschberger K, Lobbins P, Grove L, Cai X, Sethi S: Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit. Care Med 2008; 7: 853-860. (Pubitemid 351600663)
7. Sakuo Y, Yukiyoshi H, Sachiyo O, et al: Role of ciprofloxacin in its synergistic effect with fosfomycin on drug-resistant strains of Pseudomonas aeruginosa . Chemotherapy 2007; 53: 202-209.
8. Song Z, Wu H, Ciofu O, Kong KF, Hoiby N, Rygaard J, Kharazmi A, Mathee K: Pseudomonas aeruginosa alginate is refractory to Th1 immune response and impedes host immune clearance in a mouse model of acute lung infection. J Med Microbiol 2003; 52: 731-740. (Pubitemid 37174773)
9. Katsunori Y, Misuzu K, Norihide H, et al: Telithromycin inhibits the number of viable bacteria but not lymphocyte accumulation in a murine model of chronic respiratory infection. Chemotherapy 2007; 53: 10-13.
10. Young KK, Yoon YJ, Eun SH, Chung SL: Depressant effect of ambroxol on stimulated functional responses and cell death in rat alveolar macrophages exposed to silica in vitro. J Pharmacol Exp Ther 2002; 300: 629-637.
11. Nowak D, Pietras T, Antczak A, Krol M: Inhibition of endotoxin-induced lipid peroxidation by ambroxol in mice. Lung Respir 1993; 10: 14-15.
12. Yang H, Yu J, Li F, et al: Effects of ambroxol on the permeability of ciprofloxacin across the bacterial biofilm of Pseudomonas aeruginosa . J Chin Antibiot 2007; 32: 223-226.
13. Li F, Yu J, Yang H, et al: The effects of ambroxol on alginate of mature Pseudomonas aeruginosa biofilms. Curr Microbiol 2008; 57: 1-7.
14. Yanagihara K, Tomono K, Sawai T, et al: Efficacy of erythromycin inhalation in chronic respiratory infection caused by Pseudomonas aeruginosa. Kansenshogaku Zasshi (in Japanese) 1997; 71: 337-341.
15. Song Z, Kharazmi A, Wu H, Faber V, Moser C, Krogh HK, Rygaard J, Høiby N: Effects of ginseng treatment on neutrophil chemiluminescence and immunoglobulin G subclasses in a rat model of chronic Pseudomonas aeruginosa pneumonia. Clin Diagn Lab Immunol 1998; 5: 882-887. (Pubitemid 28519268)
16. Alvarez-Lerma F, Palmoar M, Martinez-Pellus AE, et al: Aetiology and diagnostic techniques in intensive care-acquired pneumonia: a Spanish multicenter study. Clin Intensive Care 1997; 8: 164-170. (Pubitemid 27389161)
17. Wilson JW, Schurr MJ, LeBlanc CL, Ramamurthy R, Buchanan KL, Nickerson CA: Mechanisms of bacterial pathogenicity. Postgrad Med 2002; 78: 216-224. (Pubitemid 34293322)
18. Oliver A, Canton R, Campo P, Baquero F, Blazquez J: High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288: 1251-1254.
19. Hassett DJ, Cuppoletti J, Trapnell B, et al: Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. Adv Drug Deliv Rev 2002; 54: 1425-1443. (Pubitemid 35375769)
20. Worlitzsch D, Tarran R, Ulrich M, et al: Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Investig 2002; 109: 317-325. (Pubitemid 34141805)
21. Remminghorst U, Rehm BHA: In vitro alginate polymerization and the functional role of Alg8 in alginate production by Pseudomonas aeruginosa . Appl Environ Microbiol 2006; 72: 298-305.
22. Pedersen SS, Høiby N, Espersen F, Koch C: Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax 1992; 47: 6-13.
23. Moser C, Johansen HK, Song Z, Hougen HP, Rygaard J, Høiby N: Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Th1 responding C3H/HeN mice. Acta Pathol Microbiol Immunol Scand 1997; 105: 838-842. (Pubitemid 27483630)
24. Yu H, Hanes M, Chrisp CE, Boucher JC, Deretic V: Microbial pathogenesis in cystic fibrosis: pulmonary clearance of mucoid Pseudomonas aeruginosa and inflammation in a mouse model of repeated respiratory challenge. Infect Immun 1998; 66: 280-288. (Pubitemid 28018831)
25. Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB, Ghnaim H, Berger M: Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995; 152: 2111-2118.
26. Mathee K, Ciofu O, Sternberg C, et al: Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology 1999; 145: 1349-1357. (Pubitemid 29294920)